5 Stocks Dragging The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 21 points (0.1%) at 16,093 as of Tuesday, Nov. 26, 2013, 11:45 AM ET. The NYSE advances/declines ratio sits at 1,560 issues advancing vs. 1,331 declining with 131 unchanged.

The Drugs industry currently sits up 0.9% versus the S&P 500, which is up 0.1%. On the negative front, top decliners within the industry include Shire ( SHPG), down 1.1%, and GlaxoSmithKline ( GSK), down 0.9%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Alexion Pharmaceuticals ( ALXN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Alexion Pharmaceuticals is down $0.79 (-0.7%) to $121.38 on light volume. Thus far, 181,597 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 973,600 shares. The stock has ranged in price between $120.22-$122.87 after having opened the day at $122.26 as compared to the previous trading day's close of $122.17.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $24.1 billion and is part of the health care sector. The company has a P/E ratio of 69.4, above the S&P 500 P/E ratio of 17.7. Shares are up 31.0% year to date as of the close of trading on Monday. Currently there are 14 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk